Weekly Dose of Optimism #195 · Not Boring by Packy McCormick
Health & Medicine · May 29, 2026
Observational studies show GLP-1 drugs are associated with significantly lower tumor progression and mortality across multiple cancers (e.g., lung 10% vs 22%; breast 10% vs 20%), though the biological mechanism is unresolved, which could expand GLP-1 value into oncology and prompt more trials, payer debates, and competitive advantages for established GLP-1 companies.
Weekly Dose of Optimism #195 · Not Boring by Packy McCormick
Health & Medicine · May 29, 2026
A single-dose PCSK9 gene-editing therapy (VERVE-102) produced large, dose-dependent reductions in PCSK9 (51–88%) and LDL cholesterol (9–62%) in a phase 1 open-label trial of 35 people—strongest at 1.0 mg/kg—and if durability and safety are confirmed it could shift cardiovascular prevention from chronic PCSK9 drugs to a one-time procedural intervention.
Weekly Dose of Optimism #195 · Not Boring by Packy McCormick
Science, Technology & Innovation · May 29, 2026
Researchers experimentally demonstrated atomically precise mechanosynthesis by depositing carbon dimers onto patterned reactive sites on a hydrogenated silicon surface using inverted-mode STM, providing the long-theorized dimer-placement primitive and shifting attention from feasibility to scaling and 3D/parallel fabrication.
Weekly Dose of Optimism #195 · Not Boring by Packy McCormick
Business, Finance & Industries · May 29, 2026
Hermeus flew an unmanned jet supersonically at Mach 1.21 and used that de-risking milestone to expand a Defense Innovation Unit contract from $159M to $219M for higher‑Mach operations and payload release, narrowing the gap between startup prototypes and defense‑relevant systems and showing milestone‑based tests can unlock bigger government contracts.
Weekly Dose of Optimism #195 · Not Boring by Packy McCormick
Science, Technology & Innovation · May 29, 2026
NASA’s Artemis Moon Base roadmap moves to a staged, partnership-based lunar South Pole buildout—Moon Base I using Blue Origin’s Blue Moon Mark 1 Endurance to Shackleton Connecting Ridge (no earlier than fall 2026), Moon Base II using Astrobotic’s Griffin to deliver >500 kg including Astrolab’s FLIP rover, and Moon Base III expanding scientific payloads—creating an iterative infrastructure model that signals industry demand for cargo delivery, rover systems, autonomous operations, logistics, and repeatable scientific instrumentation.